Oncology News | pharmaphorum

News

Essential adds neuroblastoma drug with Renaissance buy

Essential Pharma has bought fellow UK drugmaker Renaissance Pharma, adding its first development-stage drug candidate, a therapy for hard-to-treat rare cancer neuroblastom

News

Bayer, Google partner on AI for time-pressed radiologists

Bayer has joined forces with Google Cloud to continue development of an artificial intelligence-powered platform to help radiologists diagnose patients quicker and more ef

News

UK survey finds deep ethnic divisions in cancer diagnosis

A UK report has found that people from minority ethnic backgrounds face an average delay of a year between first noticing symptoms and gaining a diagnosis, which is more t

News

Study points to weaknesses in FDA accelerated approval path

Less than half of the cancer therapies that were granted accelerated approval by the FDA between 2013 and 2017 showed a clinical benefit in a confirmatory trial within the

News

Enhertu gets FDA nod for tumour-agnostic HER2 cancers

The FDA has approved the use of AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate Enhertu for all HER2-positive solid tumours, in a first for both HER2 inhibitors a

News

Carvykti, Abecma move earlier in multiple myeloma treatment

Johnson & Johnson and Legend Biotech’s BCMA-targeted CAR-T therapy Carvykti has been approved by the FDA to treat patients with multiple myeloma after at least one pri

Essential adds neuroblastoma drug with Renaissance buy

Bayer, Google partner on AI for time-pressed radiologists

UK survey finds deep ethnic divisions in cancer diagnosis

Study points to weaknesses in FDA accelerated approval path

Enhertu gets FDA nod for tumour-agnostic HER2 cancers

Carvykti, Abecma move earlier in multiple myeloma treatment

Sanofi's bispecific lunsekimig has mixed readouts in phase 2

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks